Theravance Biopharma (TBPH) Current Assets (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Current Assets data on file, last reported at $417.6 million in Q1 2026.

• On a quarterly basis, Current Assets rose 177.93% year-over-year to $417.6 million in Q1 2026; TTM through Mar 2026 was $417.6 million, a 177.93% increase from a year earlier, with the FY2025 full-year figure at $418.5 million, up 159.8% from the prior year.
• Current Assets for Q1 2026 stood at $417.6 million, roughly flat from $418.5 million in the prior quarter.
• Over the last five years, Current Assets for TBPH reached as high as $511.7 million in Q3 2022 and fell as low as $116.5 million in Q3 2024.
• Historically, Current Assets has averaged $247.2 million across 5 years, with a median of $192.0 million in 2023.
• Across the five-year window, Current Assets plunged 68.4% in 2023 and surged 207.02% in 2025, its largest moves.
• Year by year, Current Assets stood at $353.5 million in 2022, then plunged by 62.22% to $133.5 million in 2023, then rose by 20.61% to $161.1 million in 2024, then soared by 159.8% to $418.5 million in 2025, then declined by 0.2% to $417.6 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $417.6 million in Q1 2026, $418.5 million in Q4 2025, and $354.7 million in Q3 2025.